118 related articles for article (PubMed ID: 2682370)
1. [The L.A.I. test and tumor markers (Ca 19-9 and TPA) in the diagnosis of pancreatic carcinoma].
Meduri F; Bizzarini M; Diana F; Merenda R; Gerunda GE; Doni MG; Maffei Faccioli A
Minerva Chir; 1989 Aug; 44(15-16):1777-81. PubMed ID: 2682370
[TBL] [Abstract][Full Text] [Related]
2. The role of the leukocyte adherence inhibition (LAI), CA 19-9, and tissue polypeptide antigen (TPA) tests in the diagnosis of pancreatic cancer.
Meduri F; Doni MG; Merenda R; Bizzarini M; Neri D; Gerunda GE; Maffei Faccioli A
Cancer; 1989 Sep; 64(5):1103-6. PubMed ID: 2667748
[TBL] [Abstract][Full Text] [Related]
3. [Value and limitations of neoplasm markers in the diagnosis of pancreatic carcinoma].
Fabris C; Basso D; Meggiato T; Del Favero G; Fogar P; Panozzo MP; Ferrara C; Scalon P; Naccarato R
Recenti Prog Med; 1991 Mar; 82(3):166-72. PubMed ID: 2047559
[TBL] [Abstract][Full Text] [Related]
4. [Tumor markers of pancreatic cancer].
Takami H; Hishinuma S; Shintoku J; Furuuchi T; Ogata Y; Abe O
Gan To Kagaku Ryoho; 1985 Feb; 12(2):212-9. PubMed ID: 3855615
[TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of tissue polypeptide antigen (TPA) in the diagnosis of pancreatic carcinoma.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttila I
Anticancer Res; 1993; 13(5C):1883-7. PubMed ID: 8267397
[TBL] [Abstract][Full Text] [Related]
6. [The role of CEA, CA 19-9 and TPA in the diagnosis of pancreatic cancer. Evaluation by discriminant analysis].
Basso D; Fabris C; Del Favero G; Panucci A; Piccoli A; Plebani M; Pedrazzoli S; Baccaglini U; Lise M; Burlina A
Minerva Med; 1986 Apr; 77(16):613-6. PubMed ID: 3458035
[TBL] [Abstract][Full Text] [Related]
7. [Tumor markers in the diagnosis of pancreatic carcinoma].
Lemma F; Bombardieri T; Salibra M; Trovato P; De Pasquale MC; Faraone V; Punturiero R; Di Mauro S
Minerva Med; 1989 Jul; 80(7):645-9. PubMed ID: 2779818
[No Abstract] [Full Text] [Related]
8. [Clinical evaluation of CA 19-9, TPA, IAP and 5'-NPD-V as tumor markers of hepatocellular, bile duct and pancreas carcinoma].
Takahashi H; Miyazaki H; Deura M; Shimizu Y; Asukata I; Kameda H
Gan No Rinsho; 1985 May; 31(6 Suppl):623-30. PubMed ID: 2411964
[TBL] [Abstract][Full Text] [Related]
9. Serum markers and clinical data in diagnosing pancreatic cancer: a contrastive approach.
Fabris C; Del Favero G; Basso D; Piccoli A; Meggiato T; Angonese C; Plebani M; Leandro G; Burlina A; Naccarato R
Am J Gastroenterol; 1988 May; 83(5):549-53. PubMed ID: 3163228
[TBL] [Abstract][Full Text] [Related]
10. [Diagnostic usefulness of serum levels of pancreatic oncofetal antigen (POA) and CA 19-9 in pancreatic cancers: monitoring of postoperative recurrences].
Takami H; Hishinuma S; Shintoku J; Ogata Y; Abe O
Gan No Rinsho; 1985 May; 31(6 Suppl):631-7. PubMed ID: 3861883
[TBL] [Abstract][Full Text] [Related]
11. Tissue polypeptide antigen, galactosyltransferase isoenzyme II and pancreatic oncofetal antigen serum determination: role in pancreatic cancer diagnosis.
Basso D; Fabris C; Panucci A; Del Favero G; Angonese C; Plebani M; Petrin P; Burlina A; Naccarato R
Int J Pancreatol; 1988; 3 Suppl 1():S95-100. PubMed ID: 3145303
[TBL] [Abstract][Full Text] [Related]
12. CA 19-9 assay in differential diagnosis of pancreatic carcinoma from inflammatory pancreatic diseases.
Piantino P; Andriulli A; Gindro T; Pecchio F; Masoero G; Cavallini G; Naccarato R; Dobrilla G
Am J Gastroenterol; 1986 Jun; 81(6):436-9. PubMed ID: 3458359
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse.
Nicolini A; Caciagli M; Zampieri F; Ciampalini G; Carpi A; Spisni R; Colizzi C
Cancer Detect Prev; 1995; 19(2):183-95. PubMed ID: 7750106
[TBL] [Abstract][Full Text] [Related]
14. [Pretreatment evaluation of CA 72.4 in patients with carcinoma of the stomach (0-IV stage) versus CEA, TPA, CA 19-9, FER].
Buda F; Aragona P; Giani G; Sisto R; Di Nardo G; Binotto F; Gangemi P; De Zerbi T; Gentile G; Papadia A
G Ital Oncol; 1989; 9(2-3):67-72. PubMed ID: 2767730
[TBL] [Abstract][Full Text] [Related]
15. [Serum CA 125 and TPA determination in malignant neoplasms of the uterus].
Gadducci A; Facchini V; Bartolini T; Fioretti P
Ann Ostet Ginecol Med Perinat; 1988; 109(3):151-5. PubMed ID: 3207319
[No Abstract] [Full Text] [Related]
16. [Biohumeral markers in the diagnosis of pancreatic carcinoma].
Panucci A; Del Favero G; Falmis C; Brosolo P; Basso D; Pedrazzoli S; Baccaglini U; Marchioro L; Bonvilini P; Naccarato R
Recenti Prog Med; 1985; 76(7-8):385-91. PubMed ID: 3865269
[No Abstract] [Full Text] [Related]
17. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
[TBL] [Abstract][Full Text] [Related]
18. [Clinical evaluation of CA 19-9 for the detection of malignant tumors--a comparison with CEA and IAP].
Furukawa M; Kazaka S; Kushibiki K; Ashida Y; Saito H; Yamamoto H; Furukawa T
Gan No Rinsho; 1984 Apr; 30(4):357-62. PubMed ID: 6587133
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of new three tumor markers for pancreatic carcinoma: CA19/9, CA 125 and DuPan 2].
Ohkura H; Sakawaki T
Gan No Rinsho; 1985 May; 31(6 Suppl):583-8. PubMed ID: 3861882
[TBL] [Abstract][Full Text] [Related]
20. Tumor markers in pancreatic cancer--current concepts.
Schmiegel W
Hepatogastroenterology; 1989 Dec; 36(6):446-9. PubMed ID: 2693300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
